A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases - Scorecard - MDSpire
Advertisement
A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastases
Clinical Scorecard: An In Vitro Drug Screening Platform Compatible with Clinical Applications Reveals Treatment Vulnerabilities in Primary Brain Metastasis Cultures
At a Glance
Category
Detail
Condition
Brain metastases (BMs) from metastatic cancers including lung, breast, kidney, colon carcinomas, and melanoma
Key Mechanisms
Tumor cell isolation from BMs, establishment of patient-derived tumor spheroid cultures, high-throughput drug screening integrated with genetic profiling
Target Population
Patients with brain metastases from various primary cancers, often with prior multiple treatments
Care Setting
Neurosurgical and clinical oncology settings with access to molecular diagnostics and personalized medicine platforms
Key Highlights
Brain metastases occur in approximately 20–25% of metastatic cancer patients and are 10 times more frequent than primary brain tumors.
Development of a pipeline using low-passage patient-derived tumor spheroid cultures for in vitro drug sensitivity testing.
Integration of drug response data with tumor genetic alterations to identify personalized therapeutic options.
Use in vitro drug screening on patient-derived BM cultures to identify individualized treatment vulnerabilities.
Consider molecularly targeted pharmacotherapy and immune checkpoint inhibitors based on genetic and drug sensitivity profiles.
Incorporate stereotactic radiosurgery as a treatment modality where appropriate.
Monitoring & Follow-up
Evaluate tumor response through integrated clinical and molecular assessments.
Monitor for resistance development given prior multiple lines of therapy in BM patients.
Risks
Heterogeneity and complexity of BM patient population complicate treatment standardization.
Potential resistance to multiple therapies due to prior treatments for primary cancers.
Limited median overall survival despite improved treatment options.
Patient & Prescribing Data
Patients with brain metastases from diverse primary tumors, often heavily pretreated
Personalized drug screening combined with genetic profiling can reveal effective therapeutic vulnerabilities not apparent from standard clinical assessment.
Clinical Best Practices
Obtain informed consent and ethical approval for use of patient tissue in research and personalized testing.
Establish and maintain low-passage 3D tumor spheroid cultures to preserve tumor characteristics.
Use validated protocols for tissue processing, cell culture, immunohistochemistry, and molecular sequencing.
Integrate molecular and drug sensitivity data to guide personalized treatment decisions.
Consider the heterogeneity of BM and prior treatment history when interpreting drug screening results.
by Sebastian Jeising, Ann-Christin Nickel, Johanna Trübel, Jörg Felsberg, Daniel Picard, Gabriel Leprivier, Marietta Wolter, My Ky Huynh, Marlene B. Olivera, Kerstin Kaulich, Lena Häberle, Irene Esposito, Gunnar W. Klau, Julia Steinmann, Thomas Beez, Marion Rapp, Michael Sabel, Sascha Dietrich, Marc Remke, Jan F. Cornelius, Guido Reifenberger, Nan Qin
